New application of aminoquinol

Abstract

The invention discloses a new application of Rafoxanide. The influence of Rafoxanide to the skin cancer cell lines A375 and A431 is tested through a series of experiments, and the experiments indicate that the Rafoxanide is a target CDK4 / 6 inhibitor and can increase the number of cells of A375 and A431 stagnating in the G1 stage and reduce the number of the cells in the S stage; the apoptosis rate of A375 and A431 can be increased; the protein expression of the CDK 4 / 6, cyclinD and pho-CDK4 / 6 of the signal channel in the G1 stage of a cell cycle can be inhibited, a skin cancer-resistant effect is realized, and thus, the Rafoxanide can be used for preparing anti-cancer medicines for treating skin cancer; and since the Rafoxanide is a medicine resisting parasitic diseases already registered by FDA, the later clinical experiment cost is reduced, the medicine development time is shortened, and the cost and time for developing a new anti-cancer medicine are greatly saved.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a new application of Rafoxanide. Background technique [0002] Cell cycle disorder is a sign of malignant tumor formation. The activation and inactivation of cyclin-dependent kinases (CDKs) maintain the orderly progress of each phase of the cell cycle. CDK4,6 is a key regulatory factor in the early stage of the G1 phase of the cell cycle. Inhibiting the cyclin-dependent kinase CDK4,6 can inhibit the proliferation of tumor cells and is a good tumor drug target. Drugs with the activity of sex kinase CDK4, 6 can inhibit the proliferation of tumor cells and exert the effect of anti-skin cancer; there are no good anti-skin cancer chemotherapy drugs clinically, and the clinical anti-cancer chemotherapy drugs have strong side effects, so the current clinical The chemotherapy drugs used on the skin are very limited in use, so it is extremely urgent to find new and good anti-skin cancer drugs. ...

AI Technical Summary

Problems solved by technology

CDK4,6 is a key regulatory factor in the early stage of the G1 phase of the cell cycle. Inhibiting the cyclin-dependent kinase CDK4,6 can inhibit the proliferation of tumor cells and is a good tumor drug target. Drugs with the activity of sex kinase CDK4, 6 can inhibit the proliferation of tumor cells and exert the effect of anti-skin cancer; there are no good anti-skin cancer chemotherapy drugs clinically, and the clinical anti-cancer chemotherapy drugs have strong side effects, so the current clinical Chemotherapy drugs used on the skin are very limited in use, so it is imminent to find new and good anti-skin cancer drugs

Images